Experts calls for more active new drug development

The government’s plan to slash insurance-covered drug prices in April would establish grounds to reinforce fundamentals of the Korean drug sector and to shift from generic manufacturing to novel pharmaceutical innovation, experts claim.

“Large companies are reluctant to embark on drug development because it costs enormous amounts of time and money with no assurance of success. This triggered...